Search

Displaying results 1161 - 1170 of 9323 in total
  1. Drug

    Lithium carbonate

    go.drugbank.com/drugs/DB14509
    ApprovedInvestigational

    Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. … Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Euro Lithium
  2. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … [A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.

  3. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. … [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual

  4. Drug

    Hydrocodone

    go.drugbank.com/drugs/DB00956
    ApprovedIllicitInvestigational

    [T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Clopidogrel

    go.drugbank.com/drugs/DB00758
    ApprovedInvestigational

    Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. … in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and

    Mixtures: CLOPIDOGREL E ACIDO ACETILSALICILICO VIATRIS, CLOPIDOGREL E ACIDO ACETILSALICILICO VIATRISProducts: CLOPIDOGREL E ACIDO ACETILSALICILICO BILLEV
  6. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.

    Products: Alfuzosin PH&T 10mg prolonged-release tablets
  7. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration

    Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamideMixtures: LEVO C/E BETA100/25/200, LEVO C/E BETA100/25/200
  8. Drug

    Estradiol acetate

    go.drugbank.com/drugs/DB13952
    ApprovedVet approved

    The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  9. Drug

    Trovafloxacin

    go.drugbank.com/drugs/DB00685
    ApprovedWithdrawn

    Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. … It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones.

  10. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    formulated at 75% of the strength of the existing intranasal product. … Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome